ASCO GU 2025

ASCO GU 2025

Details: 18 February 2025

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a case-based session discussing treatment options for renal cell cancer following failure of immunotherapy.

Details: 18 February 2025

Reno, Nevada (UroToday.com) -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), in San Francisco. The abstract discusses the role of Blue Light Cystoscopy in identifying tumors undetected by WLC leading to necessary upstaging of patient pathology. Consequently, when using Blue Light Cystoscopy with Cysview, bladder cancer management decisions can be made more appropriately.

Details: 18 February 2025

(UroToday.com) The 2025 GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Daniel Castellano discussing overcoming the challenges of antibody drug conjugate toxicity in bladder cancer. Dr. Castellano started his presentation by reviewing the categorization of adverse events by grade using the CTCAE, with grade referring to the severity of the adverse event:

Details: 18 February 2025

(UroToday.com) The 2025 GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with antibody drug conjugates. Dr. Jiang started her presentation by noting that the treatment of metastatic urothelial cancer prior to antibody drug conjugates was associated with a median overall survival for patients with metastatic urothelial carcinoma of 15 months.

Details: 18 February 2025

(UroToday.com) The 2025 GU ASCO annual meeting featured a session on emerging trends in germ cell tumors and a presentation by Dr. Axel Heidenreich discussing primary retroperitoneal lymph node dissection (RPLND) in stage II seminoma. The clinical presentation of seminomas is such that <10% of patients present in de novo clinical stage IIA/B. Importantly, 15% of stage I seminoma patients relapse with 90-95% of relapses located in the retroperitoneum. Relapse free survival rates vary between 82-94% and 5-year overall survival is ~95%. Standard treatment for seminoma is (i) 3 cycles of BEP chemotherapy or 4 cycles of EP chemotherapy, (ii) radiation therapy with 30 Gy in CS IIA seminoma and 36 Gy in CS IIB seminoma, (iii) an optional treatment option is radiation therapy + 1 cycle AUC 7. With all of these treatment options, the 5-year overall survival is 95%. The problem with all of these treatments is long-term toxicity, which includes additional solid cancers, leukemia, cardiovascular, and diabetes mellitus:

Details: 18 February 2025

(UroToday.com) The 2025 GU ASCO annual meeting featured a session on emerging trends in germ cell tumors and a presentation by Dr. Darren Feldman discussing the landscape of new trials and targets in refractory germ cell tumors. For the definition of this talk, Dr. Feldman notes that relapsed/refractory germ cell tumor is a germ cell tumor that is probably not curable. This includes most patients with:

Details: 18 February 2025

(UroToday.com) The 2025 GU ASCO annual meeting featured a session on emerging trends in germ cell tumors and a presentation by Dr. Nabil Adra discussing the current evidence and indications for high-dose chemotherapy in testicular cancer. Dr. Adra highlighted that 20% of patients with metastatic germ cell tumor will progress after first line therapy: 11% for good risk disease, 25% for intermediate risk disease, and 46% for poor risk disease. Progression is defined by serology and radiography, and we should use caution with initiating salvage therapy with borderline AFP and hCG. Options to treat relapsed germ cell tumors include salvage surgery, standard-dose chemotherapy, and high-dose chemotherapy. The International Prognostic Factors Study Group previously established prognostic variables as:

Details: 18 February 2025

(UroToday.com) The 2025 GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Funda Meric-Bernstam discussing HER2 antibody drug conjugate therapy, a new frontier in bladder cancer. Dr. Meric-Bernstam started her presentation by highlighting that bladder cancer has a HER2 alteration incidence of 12.4%. Across all cancers, 2.7% are HER2 IHC 3+:

Details: 18 February 2025

(UroToday.com) The 2025 GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Terence Friedlander discussing novel drug combinations with antibody drug conjugates. One of the main reasons why we should pursue combination therapy in metastatic urothelial carcinoma is that there is attrition of patients across lines of therapy:

Details: 18 February 2025

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Jesus Casillas discussing a pooled analysis of SOLAR and SATURN clinical trials comparing progression following systemic and tumor-directed therapy for de novo versus recurrent PSMA PET–defined oligo-M1 prostate cancer. Oligometastatic castration sensitive prostate cancer (CSPC) presents a unique opportunity for curative or long term disease control through targeted and systemic therapies. Emerging studies favor a multimodal approach, combining treatment of the primary and metastases with short term intensified systemic therapy, aiming to improve survival and local control while minimizing toxicity from indefinite systemic therapy. This post-hoc analysis of the SOLAR (NCT03298087) and SATURN (NCT03902951) trials, which evaluated systemic and tumor-directed therapy in PSMA-PET defined oligo-M1 (≤5 metastases) de novo and recurrent oligometastatic CSPC, respectively, aims to draw inferences on biology and oncologic outcome.

Details: 18 February 2025

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. William Kelly discussing beyond PSMA-targeted agents for advanced disease. Dr. Kelly notes that there are several important considerations for targets for radioligand therapy:

Details: 18 February 2025

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Glenn Bauman discussing a prospective provincial registry of PSMA PET/CT for recurrent prostate cancer. While most prostate cancer is initially localized, about 25% of patients treated with surgery or radiation experience biochemical failure, and traditional imaging struggles to detect sites of these recurrences early. PSMA PET/CT scanning has emerged as a more effective tool for detecting recurring prostate cancer, potentially enabling earlier treatment interventions. PREP was initiated in Ontario to provide access and characterize the performance of PSMA PET CT (¹⁸F-DCFPyL PSMA PET-CT) among men with recurrent prostate cancer after primary definitive treatment (radical prostatectomy or radiation therapy).

Details: 18 February 2025

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Benjamin Maughan discussing a prospective trial of a structured exercise program to lessen fatigue in patients with advanced prostate cancer undergoing androgen deprivation therapy (ADT). Cancer-related fatigue, one of the most significant issues affecting quality of life, is reported by up to 75% of men with advanced prostate cancer on ADT. Importantly, exercise may serve as a tool to improve fatigue in cancer patients. As such, Dr. Maughan and colleagues examined the effect of a structured exercise program on fatigue in men with advanced prostate cancer.

Details: 18 February 2025

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Melissa Abel discussing radium-223 without androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer and PET findings in the bones. Biochemically recurrent prostate cancer patients have a rising PSA after definitive surgery or radiation, but negative CT/⁹⁹Tc scans. While ADT-based strategies are commonly used, they can be associated with life-altering toxicities and have not been shown to improve survival.

Details: 18 February 2025

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic castration-resistant prostate cancer (mCRPC) starting first-line androgen receptor signaling inhibitor therapy.

Details: 18 February 2025

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA was host to a session on the current state and future directions of biomarkers and adjuvant therapy for renal cell carcinoma (RCC). Dr. Samra Turajlic discussed the future of biomarkers in RCC.

Details: 18 February 2025

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Alicia K. Morgans, MD, MPH, discussing ARASTEP, a phase 3, randomized, double-blind, placebo-controlled study assessing darolutamide + ADT in patients with high-risk biochemical recurrence of prostate cancer. Patients with prostate cancer treated with radiotherapy or radical prostatectomy as primary therapy may develop biochemical recurrence of prostate cancer, defined by a PSA increase with no evidence of metastases on conventional imaging.

Details: 18 February 2025

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA was host to a session on the current state and future directions of biomarkers and adjuvant therapy for renal cell carcinoma (RCC). Dr. Simpa Salami discussed the need for clinically actionable biomarkers to risk stratify patients, predict treatment responses for guiding decision making, and the incorporation of biomarkers and correlative studies into clinical trials.

Details: 18 February 2025

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Lisa Marie Gudenkauf discussing the implementation and preliminary validity of the Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) in patients receiving radionuclide therapy for prostate cancer.

Details: 18 February 2025

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Alejandro Sanchez discussing SOAR, a phase II trial of image-guided oligometastatectomy and radiation therapy in recurrent prostate cancer. In a subset of patients with molecular-imaging defined recurrent oligometastatic prostate cancer, salvage oligometastatectomy with surgery and/or radiation may provide improved ADT-free survival.